Rockville, Md. — February 12, 2026 — Leads & Copy — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will report its fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
The biopharmaceutical company, which focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, will host a conference call on Tuesday, February 24, 2026, at 4:30 p.m. ET to discuss the results.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host the call. Management will provide prepared remarks and discuss business results, followed by a question-and-answer session.
A live webcast will be available in the Events & Presentations section of the company’s Investor Relations website at www.supernus.com/Investors.
Participants can pre-register for the call at any time before the start here. Upon completion of registration, participants will receive a dial-in number and personalized conference code to access the call. Participants should dial in 15 minutes before the start time.
A replay of the live call will be available on the company’s Investor Relations website at www.supernus.com/Investors. The webcast will be available on the website for 60 days following the live call.
Supernus Pharmaceuticals is focused on developing and commercializing products for CNS diseases. The company’s neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus is also developing product candidates for CNS disorders.
Source: Supernus Pharmaceuticals, Inc.
